Skip to main content

Tazicef Novaplus Side Effects

Generic name: ceftazidime

Medically reviewed by Drugs.com. Last updated on Jan 20, 2024.

Note: This document contains side effect information about ceftazidime. Some dosage forms listed on this page may not apply to the brand name Tazicef Novaplus.

Applies to ceftazidime: injection powder for solution.

Serious side effects of Tazicef Novaplus

Along with its needed effects, ceftazidime (the active ingredient contained in Tazicef Novaplus) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking ceftazidime:

Less common

Rare

Incidence not known

Other side effects of Tazicef Novaplus

Some side effects of ceftazidime may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to ceftazidime: injectable powder for injection, intravenous powder for injection, intravenous solution.

Hepatic

Common (1% to 10%): Transient elevations in 1 or more liver enzymes (alkaline dehydrogenase, ALT, AST, GGT)

Very rare (less than 0.01%): Jaundice

Postmarketing reports: Cholestasis, hyperbilirubinemia, liver dysfunction[Ref]

Local

Common (1% to 10%): Inflammation, pain, phlebitis, thrombophlebitis

Frequency not reported: Superficial desquamation around injection site[Ref]

Inflammation and pain occurred after IM administration.

Phlebitis and thrombophlebitis occurred with IV administration.[Ref]

Hematologic

Approximately 5% of patients developed a positive Coombs test.[Ref]

Common (1% to 10%): Eosinophilia, positive Coombs test, thrombocytosis

Uncommon (0.1% to 1%): Leukopenia, neutropenia, thrombocytopenia

Frequency not reported: Agranulocytosis, hemolytic anemia, lymphocytosis, positive Coombs test without hemolysis

Postmarketing reports: Aplastic anemia, pancytopenia, prothrombin time prolonged[Ref]

Dermatologic

Common (1% to 10%): Maculopapular rash, rash, urticarial rash

Uncommon (0.1% to 1%): Pruritus

Very rare (less than 0.01%): Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis

Frequency not reported: Drug reaction with eosinophilia and systemic symptoms (DRESS)

Postmarketing reports: Urticaria[Ref]

Gastrointestinal

Common (1% to 10%): Diarrhea

Uncommon (0.1% to 1%): Abdominal pain, antibacterial agent-associated colitis/diarrhea, colitis, nausea, vomiting

Frequency not reported: Pseudomembranous colitis[Ref]

Pseudomembranous colitis may have been presented as diarrhea or colitis.[Ref]

Metabolic

Common (1% to 10%): Transient elevations in LDH

Postmarketing reports: False-positive test for urinary glucose[Ref]

Renal

Uncommon (0.1% to 1%): Transient elevations of blood urea/blood urea nitrogen (BUN)/serum creatinine

Very rare (less than 0.01%): Acute renal failure, interstitial nephritis

Postmarketing reports: Renal dysfunction, toxic nephropathy[Ref]

Nervous system

Neurological sequelae occurred in patients with renal dysfunction who did not receive appropriate dose adjustments and included coma, convulsions, encephalopathy, myoclonia, and tremor.[Ref]

Uncommon (0.1% to 1%): Dizziness, headache

Very rare (less than 0.01%): Bad taste, paresthesia,

Frequency not reported: Asterixis, coma, convulsions, encephalopathy, myoclonia, neurological sequelae, neuromuscular excitability, seizures, tremor[Ref]

Immunologic

Uncommon (0.1% to 1%): Candidiasis, oral thrush[Ref]

Genitourinary

Uncommon (0.1% to 1%): Vaginitis[Ref]

Other

Uncommon (0.1% to 1%): Fever[Ref]

Hypersensitivity

Anaphylaxis included bronchospasm, cardiopulmonary arrest, and/or hypotension.[Ref]

Very rare (less than 0.01%): Anaphylaxis, angioedema

Postmarketing reports: Allergic reactions[Ref]

Cardiovascular

Very rare (less than 0.01%): Hypotension

Frequency not reported: Hot flushes

Postmarketing reports: Cardiopulmonary arrest, hemorrhage[Ref]

Respiratory

Very rare (less than 0.01%): Bronchospasm[Ref]

References

1. (2002) "Product Information. Fortaz (ceftazidime)." Glaxo Wellcome

2. (2002) "Product Information. Tazicef (ceftazidime)." SmithKline Beecham

3. (2001) "Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome

4. (2001) "Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company

5. Cerner Multum, Inc. "UK Summary of Product Characteristics."

6. Cerner Multum, Inc. "Australian Product Information."

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.